Full-Time

Senior/Principal Scientist

Lung Cancer Research

Posted on 2/2/2024

23andMe

23andMe

501-1,000 employees

Direct-to-consumer DNA testing services

Compensation Overview

$160k - $240k/yr

Senior

Sunnyvale, CA, USA

Requires onsite presence in Sunnyvale, CA for a minimum of 3 days per week.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Science
Data Analysis
Requirements
  • PhD or MD with 5 years of research experience in oncology post graduate degree
  • Ability to be able to provide direction for a large scale lung cancer cohort study while incorporating strategic scientific and business goals
  • Expertise in clinical research, longitudinal research, epidemiological modeling, or computational biology preferred
  • Expertise or hands-on experience with 'big data' and/or natural history data applied to oncology
  • Ability to represent the company and the lung cancer cohort findings at appropriate scientific, non-scientific, and other professional meetings
  • Ability to establish and maintain key relationships with internal and external stakeholders, including patient advocacy groups and other community-based disease focused organizations
  • Ability to lead directly and by influence, including strong problem solving and conflict resolution skills
  • Exceptional communication skills across many mediums. Demonstrated ability to communicate clearly, concisely, and empathetically to both scientific and non-scientific audiences
Responsibilities
  • provide scientific and strategic leadership for research initiatives involving our lung cancer cohort
  • responsible for the scientific success of the lung cancer research program
  • developing and executing a research plan to achieve the programmatic aims
  • soliciting input from key internal and external stakeholders
  • tracking project goals
  • implementing an analysis plan
  • collaboration with an external study sponsor and their advisors

23andMe offers direct-to-consumer DNA testing that provides individuals with insights into their ancestry, genetic traits, and potential health risks. Customers purchase a DNA testing kit, send in a saliva sample, and receive personalized genetic reports based on the analysis of their DNA. This service appeals to a wide range of people, from those curious about their family history to those wanting to understand their health predispositions. Unlike many competitors, 23andMe not only sells these kits but also offers subscription services for ongoing updates and insights based on new genetic research. Additionally, the company utilizes its large genetic database for research collaborations, which can lead to further revenue through partnerships with research institutions and pharmaceutical companies. The goal of 23andMe is to empower individuals with knowledge about their genetics while contributing to advancements in genetic research.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

2006

Simplify Jobs

Simplify's Take

What believers are saying

  • Rising demand for personalized medicine boosts 23andMe's health-related offerings.
  • Telehealth integration can enhance 23andMe's customer engagement and service delivery.
  • Partnerships with pharmaceutical companies offer research and development opportunities.

What critics are saying

  • 23andMe faces financial instability due to Chapter 11 bankruptcy proceedings.
  • Leadership changes create uncertainty following CEO Anne Wojcicki's resignation.
  • Data breach settlement costs and security concerns may erode customer trust.

What makes 23andMe unique

  • 23andMe offers direct-to-consumer DNA testing kits for ancestry and health insights.
  • The company collaborates with pharmaceutical firms for drug discovery using its genetic database.
  • 23andMe provides subscription services for ongoing genetic insights and updates.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health, vision, & dental plans

Family planning, support, & leave for parents

Mental healthcare

Student loan assistance

Volunteer time off

Dog friendly office

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

1%
Republican Investor
Mar 26th, 2025
23andMe bankruptcy: Will your private data be protected?

Genetic testing company 23andMe is seeking a new owner as part of its Chapter 11 bankruptcy protection proceedings.

Fox News
Mar 25th, 2025
Protect your genetic data: Urgent steps after 23andMe bankruptcy

The genetic testing company 23andMe, once a pioneer in consumer DNA testing, has filed for Chapter 11 bankruptcy amid financial struggles, a leadership shakeup and growing concerns about the security of its customers' genetic data.

The Answer Sarasota
Mar 24th, 2025
23andMe files for bankruptcy, CEO and cofounder steps down

23andMe announced Joe Selsavage, its chief financial and accounting officer, has been named interim CEO.

Hit Consultant
Mar 24th, 2025
23Andme Files For Chapter 11 Bankruptcy To Facilitate Sale

What You Should Know: – 23andMe, a human genetics and biotechnology company, has announced its decision to initiate voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the Eastern District of Missouri. – The bankruptcy filing is aimed at facilitating a structured sale process to maximize the value of its business. The company has assured its customers that operations will continue as normal and that there will be no changes to the way customer data is stored, managed, or protected.Chapter 11 Details23andMe is seeking court authorization to conduct a sale of substantially all its assets, either through a Chapter 11 plan or under Section 363 of the U.S. Bankruptcy Code. Upon court approval, the company, with the assistance of an independent investment banker, will actively solicit qualified bids over a 45-day period. If multiple bids are received, an auction will be held to ensure the highest possible value is obtained. To ensure continued operations during the proceedings, 23andMe has filed customary “first-day” motions, seeking court approval to pay employee wages and benefits, and compensate essential vendors and suppliers

In Happier News
Mar 24th, 2025
Genetic testing company 23andMe declares bankruptcy

On Sunday, the genetic testing and heritage company 23andMe announced that it had entered Chapter 11 bankruptcy and was asking a court to arrange its sale.

INACTIVE